US FDA to improve communication on risk:benefit issues
This article was originally published in SRA
The US Food and Drug Administration has developed a Strategic Plan for Risk Communication in its effort to provide healthcare professionals and consumers with more meaningful information about the benefits and risks of regulated products, ie drugs, medical devices, food and tobacco1,2.
You may also be interested in...
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.